Literature DB >> 1761778

Evidence for percutaneous inoculation as the mode of transmission for chromoblastomycosis.

H A Rubin1, S Bruce, T Rosen, M E McBride.   

Abstract

The exact pathogenesis of chromoblastomycosis is unknown. Direct percutaneous inoculation, inhalation, and hematogenous dissemination have been implicated. We report a case of chromoblastomycosis that followed a well-defined episode of penetrating trauma. The causative organism, Fonsecaea pedrosi, was cultured from the patient's lesion and from the tree branch responsible for the trauma. This "natural" experiment supports the contention that one cause of chromoblastomycosis is traumatic cutaneous implantation of the fungus.

Entities:  

Mesh：

Year:  1991        PMID： 1761778     DOI： 10.1016/0190-9622(91)70292-a

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


  9 in total

Review 1.  Chromoblastomycosis.

Authors:  Flavio Queiroz-Telles; Sybren de Hoog; Daniel Wagner C L Santos; Claudio Guedes Salgado; Vania Aparecida Vicente; Alexandro Bonifaz; Emmanuel Roilides; Liyan Xi; Conceição de Maria Pedrozo E Silva Azevedo; Moises Batista da Silva; Zoe Dorothea Pana; Arnaldo Lopes Colombo; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

2.  Auricular chromoblastomycosis: a case report and review of published literature.

Authors:  Katlein França; Ricardo Tadeu Villa; Viviane Reis de Azevedo Bastos; Ana Carolina C Almeida; Katyane Massucatti; Daniella Fukumaru; Valcinir Bedin
Journal:  Mycopathologia       Date:  2011-02-17       Impact factor: 2.574

3.  Pathogenicity and Growth Conditions Modulate Fonsecaea Extracellular Vesicles' Ability to Interact With Macrophages.

Authors:  Lucas de Oliveira Las-Casas; Clara Luna Freitas Marina; Raffael Júnio Araújo de Castro; Luísa Coutinho Coelho; Sônia Nair Báo; G Sybren de Hoog; Vânia Aparecida Vicente; Larissa Fernandes; Anamelia Lorenzetti Bocca
Journal:  Front Cell Infect Microbiol       Date:  2022-06-09       Impact factor: 6.073

4.  Chromoblastomycosis: Report of two cases on face from urban industrial area.

Authors:  Narayanan K Panicker; Shirish S Chandanwale; Yugal K Sharma; Urmi S Chaudhari; Gunjan V Mehta
Journal:  Indian Dermatol Online J       Date:  2013-10

Review 5.  Chromoblastomycosis.

Authors:  Paweł M Krzyściak; Małgorzata Pindycka-Piaszczyńska; Michał Piaszczyński
Journal:  Postepy Dermatol Alergol       Date:  2014-10-22       Impact factor: 1.837

Review 6.  Chromoblastomycosis: an etiological, epidemiological, clinical, diagnostic, and treatment update.

Authors:  Arival Cardoso de Brito; Maraya de Jesus Semblano Bittencourt
Journal:  An Bras Dermatol       Date:  2018 Jul-Aug       Impact factor: 1.896

7.  Molecular analysis and pathogenicity of the Cladophialophora carrionii complex, with the description of a novel species.

Authors:  G S de Hoog; A S Nishikaku; G Fernandez-Zeppenfeldt; C Padín-González; E Burger; H Badali; N Richard-Yegres; A H G Gerrits van den Ende
Journal:  Stud Mycol       Date:  2007       Impact factor: 16.097

8.  Chromoblastomycosis caused by Rhinocladiella aquaspersa.

Authors:  Gloria M González; O Carolina Rojas; José G González; Yingqian Kang; G S de Hoog
Journal:  Med Mycol Case Rep       Date:  2013-08-31

9.  A Model for Trans-Kingdom Pathogenicity in Fonsecaea Agents of Human Chromoblastomycosis.

Authors:  Gheniffer Fornari; Renata Rodrigues Gomes; Juliana Degenhardt-Goldbach; Suelen Silvana Dos Santos; Sandro Rogério de Almeida; Germana Davila Dos Santos; Marisol Dominguez Muro; Cleusa Bona; Rosana Herminia Scola; Edvaldo S Trindade; Israel Henrique Bini; Lisandra Santos Ferreira-Maba; Daiane Rigoni Kestring; Mariana Machado Fidelis do Nascimento; Bruna Jacomel Favoreto de Souza Lima; Morgana F Voidaleski; Douglas André Steinmacher; Bruna da Silva Soley; Shuwen Deng; Anamelia Lorenzetti Bocca; Moises B da Silva; Claudio G Salgado; Conceição Maria Pedroso E Silva de Azevedo; Vania Aparecida Vicente; Sybren de Hoog
Journal:  Front Microbiol       Date:  2018-10-09       Impact factor: 5.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.